Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Caladrius Biosciences: The Business Model is Intriguing, But the Cash Position Is Weak (CLBS, $0.57, No Opinion at this time)

Investment Overview

I am interested in Caladrius Biosciences primarily†because of the potential for its PCT cell therapy manufacturing business. PCT has…
Read more…